EpigenomicsPub Date : 2025-05-01Epub Date: 2025-04-18DOI: 10.1080/17501911.2025.2494497
Chen-Yu Yeh, Wan-Yu Lin
{"title":"Three generations of epigenetic clocks in mediating the adverse effect of smoking on metabolic health.","authors":"Chen-Yu Yeh, Wan-Yu Lin","doi":"10.1080/17501911.2025.2494497","DOIUrl":"https://doi.org/10.1080/17501911.2025.2494497","url":null,"abstract":"<p><strong>Aims: </strong>Metabolic syndrome (MetS) is a composite disorder that includes abdominal obesity, impaired glucose levels, high blood pressure, and dyslipidemia. Smoking can alter epigenetic profiles and is a critical modifiable risk factor for MetS. We aim to explore the epigenetic age acceleration (EAA) that can mainly deliver smoking influences on metabolic health.</p><p><strong>Methods: </strong>We conducted a mediation analysis of 2,474 individuals with data in the Taiwan Biobank. Current and former smoking and the respective pack-years were included as four exposure factors. Seven markers of DNA methylation (DNAm) covering three generations of epigenetic clocks were included as mediators. Seven metabolic outcomes included MetS status (yes vs. no) and six related traits.</p><p><strong>Results: </strong>GrimEAA and DunedinPACE mediated the associations of the four smoking factors with MetS, fasting glucose, triglyceride, and high-density lipoprotein cholesterol levels (false discovery rate < 0.05). GrimEAA and DunedinPACE respectively mediated 48.2% and 24.2% of current smoking's effect on MetS and 60.9% and 26.1% of current smoking pack-year's effect on MetS risk. The DNAm plasminogen activator inhibitor 1 level mediated the adverse effects of current smoking status and pack-years on all seven metabolic outcomes.</p><p><strong>Conclusion: </strong>The GrimEAA-mediated proportions were approximately two times greater than the DunedinPACE-mediated proportions.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":"17 7","pages":"453-461"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"tRF5-22-SerGCT-1 protects the heart against myocardial injury by targeting MSK1.","authors":"Fanji Meng, Hemanyun Bai, Kangling Ke, Lingyan Fang, Haitao Huang, Xiao Liang, Weiyan Li, Xiongwen Chen, Can Chen","doi":"10.1080/17501911.2025.2495544","DOIUrl":"https://doi.org/10.1080/17501911.2025.2495544","url":null,"abstract":"<p><strong>Aim: </strong>This study aims to explore the expression profiles and potential functions of tsRNAs in MI.</p><p><strong>Methods: </strong>Using a mouse model of MI induced by coronary artery ligation, we used smallRNA array to obtain tsRNAs expression profiles. Reverse transcription quantitative polymerase chain reaction(RT-qPCR), Western Blot, tRF5-22-SerGCT-1 mimics and inhibitors, cell proliferation and apoptosis detection, luciferase reporter assay, and bioinformatics analysis were employed to screen differentially expressed tsRNAs and identify the functions of tsRNAs after MI.</p><p><strong>Results: </strong>A total of 175 significantly different tsRNAs (FC > 1.5, <i>p</i> < 0.05) were identified in MI mice, including 98 upregulated and 77 downregulated tsRNAs. Bioinformatics and target gene prediction revealed that two differentially expressed tsRNAs (5'tiRNA-34-GlnCTG-4, tRF5-22-SerGCT-1) may be involved in processes like autophagy and apoptosis, as well as in key signaling pathways such as MAPK and autophagy. Further investigation of tRF5-22-SerGCT-1 revealed that its overexpression or inhibition in vitro affected MSK1 levels and cardiomyocytes apoptosis following oxygen-glucose deprivation, providing a protective effect. Dual-luciferase assays confirmed that tRF5-22-SerGCT-1 targets MSK1.</p><p><strong>Conclusion: </strong>We found differentially expressed tsRNAs in MI. In addition, our research showed first that tRF5-22-SerGCT-1 might be involved in the MAPK pathways by targeting the MSK1, modulating apoptosis.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":"17 7","pages":"439-451"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EpigenomicsPub Date : 2025-05-01Epub Date: 2025-03-28DOI: 10.1080/17501911.2025.2485019
Margaret R Brown, Yadira M Soto-Feliciano
{"title":"Menin: from molecular insights to clinical impact.","authors":"Margaret R Brown, Yadira M Soto-Feliciano","doi":"10.1080/17501911.2025.2485019","DOIUrl":"10.1080/17501911.2025.2485019","url":null,"abstract":"<p><p>Menin, the protein product of the <i>MEN1</i> gene, is essential for development and has been implicated in multiple different cancer types. These include leukemias and several different solid tumors, including neuroendocrine tumors. Menin interacts with many different protein partners and genomic loci in a context-dependent manner, implicating it in numerous cellular processes. The role of Menin varies across tumor types as well, acting as a tumor suppressor in some tissues and an oncogenic co-factor in others. Given the role of Menin in cancer, and particularly its oncogenic role in acute myeloid leukemia, the development of Menin inhibitors has been an expanding field over the past 10-15 years. Many inhibitors have been in clinical trials and one has recently received approval from the Food and Drug Administration (FDA). In this review, we explore the role of Menin in multiple cancer types, the development of Menin inhibitors and their clinical applications and what the focus of the field should be in the next 5-10 years to expand the use and efficacy of these drugs.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"489-505"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EpigenomicsPub Date : 2025-05-01Epub Date: 2025-03-18DOI: 10.1080/17501911.2025.2479424
Amit Sharma, Tikam Chand Dakal, Ingo G H Schmidt-Wolf, Jarek Maciaczyk, Giedrius Steponaitis
{"title":"Edge of RNA m6A modification on LINE-1 retrotransposons in central nervous system: merely a transcriptional control?","authors":"Amit Sharma, Tikam Chand Dakal, Ingo G H Schmidt-Wolf, Jarek Maciaczyk, Giedrius Steponaitis","doi":"10.1080/17501911.2025.2479424","DOIUrl":"10.1080/17501911.2025.2479424","url":null,"abstract":"","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"435-437"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EpigenomicsPub Date : 2025-05-01Epub Date: 2025-04-21DOI: 10.1080/17501911.2025.2489921
Natalia Atzemian, Shafeeq Mohammed, Ludovica Di Venanzio, Era Gorica, Sarah Costantino, Frank Ruschitzka, Francesco Paneni
{"title":"Cardiometabolic disease management: influences from epigenetics.","authors":"Natalia Atzemian, Shafeeq Mohammed, Ludovica Di Venanzio, Era Gorica, Sarah Costantino, Frank Ruschitzka, Francesco Paneni","doi":"10.1080/17501911.2025.2489921","DOIUrl":"https://doi.org/10.1080/17501911.2025.2489921","url":null,"abstract":"<p><p>Epigenomics is a rapidly emerging field that has gathered significant attention as a \"non-genetic determinant\" implicated in the manifestation of non-communicable diseases. Exploring epigenetic modifications provides novel insights into the management of cardiometabolic disease (CMD). Epigenetics signatures are influenced by environmental stressors such as air pollution, toxins, and urban noises as well as by established cardiovascular risk factors including smoking, sedentary lifestyle, obesity, and diabetes. Understanding how epigenetic alterations lead to CMD as well as inter-individual differences in epigenetic makeup could unveil new molecular targets and new epi-drugs to be employed for precision medicine approaches in the growing population of patients with cardiometabolic disease to reduce cardiovascular risk. Herein, we provide an overview of the latest advancements in epigenetic mechanisms implicated in CMD and possible therapeutic opportunities.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":"17 7","pages":"463-474"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EpigenomicsPub Date : 2025-04-01Epub Date: 2025-03-02DOI: 10.1080/17501911.2025.2473309
Omar Ramos-Lopez
{"title":"Epigenomic mechanisms of dietary prescriptions for obesity therapy.","authors":"Omar Ramos-Lopez","doi":"10.1080/17501911.2025.2473309","DOIUrl":"10.1080/17501911.2025.2473309","url":null,"abstract":"<p><p>Dietary modification is a cornerstone and a primary goal for weight loss, whose effects may be related to epigenetic phenomena. In this literature review, a comprehensive search without time restriction was performed in PubMed/Medline, Cochrane, SciELO, and Scopus databases to identify epigenetic signatures related to obesity outcomes upon dietary advice. In this context, experimental studies and clinical trials have identified certain DNA methylation marks, miRNA expression profiles and histone modifications putatively associated with adiposity outcomes after different nutritional interventions. These include traditional dietary patterns, diets with different macronutrient compositions, and supplementation with fatty acids, amino acids and derivatives, methyl donors, vitamins and minerals, probiotics and prebiotics, and bioactive food compounds. Some of these epigenetic signatures have been mapped to genes involved in food intake control, adipogenesis, lipolysis, fatty acid oxidation, body fat deposition, and gut microbiota modulation. However, additional studies are still required to address dosage and follow-up variability, validation of epigenetic marks, genome-wide approaches, and appropriate statistical settings. Although more investigation is required, these insights may contribute to the characterization of epigenetic biomarkers of body weight regulation toward the prescription of tailored dietary strategies targeting the epigenome for a more precise obesity management and control.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"423-434"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of IL-34 and Slc7al as potential key regulators in MASLD progression through epigenomic profiling.","authors":"Chuanfei Zeng, Mingliang Wei, Huan Li, Linxin Yu, Chuang Wang, Ziqi Mu, Ziyin Huang, Yujia Ke, Lian-Yun Li, Yong Xiao, Min Wu, Ming-Kai Chen","doi":"10.1080/17501911.2025.2467028","DOIUrl":"10.1080/17501911.2025.2467028","url":null,"abstract":"<p><strong>Objective: </strong>Epigenetic alterations are critical regulators in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD); however, the dynamic epigenomic landscapes are not well defined. Our previous study found that H3K27ac and H3K9me3 play important roles in regulating lipid metabolic pathways in the early stages of MASLD. However, the epigenomic status in the inflammation stages still needs to be determined.</p><p><strong>Method: </strong>C57BL/6 male mice were fed with the methionine- and choline-deficient (MCD) or normal diet, and their serum and liver samples were collected after 6 weeks. Serum alanine aminotransferase (ALT), aspartate amino transferase (AST), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels were measured. Chromatin immunoprecipitation sequencing (ChIP-Seq) for H3K27ac and H3K9me3 was performed together with RNA sequencing (RNA-seq) and key regulators were analyzed.</p><p><strong>Results: </strong>The target genes of enhancers with increased H3K27ac and decreased H3K9me3 signals are enriched in lipid metabolism and immuno-inflammatory pathways. <i>Il-34</i> and <i>Slc7al</i> are identified as potential regulators in MASLD.</p><p><strong>Conclusion: </strong>Our study reveals that active enhancers and heterochromatin associated with metabolic and inflammatory genes are extensively reprogrammed in MCD-diet mice, and <i>Il-34</i> and <i>Slc7al</i> are potentially key genes regulating the progression of MASLD.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"281-295"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EpigenomicsPub Date : 2025-04-01Epub Date: 2025-03-06DOI: 10.1080/17501911.2025.2476391
Saara Marttila
{"title":"Immune cell composition is an important contributor to epigenetic age variation.","authors":"Saara Marttila","doi":"10.1080/17501911.2025.2476391","DOIUrl":"10.1080/17501911.2025.2476391","url":null,"abstract":"","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"373-375"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of a chromatin regulator signature and potential candidate drugs for primary open-angle glaucoma.","authors":"Xinyue Zhang, Lulu Xiao, Xiaoyu Zhou, Jiahao Xu, Li Liao, Ping Wu, Zhimin Liao, Xuanchu Duan","doi":"10.1080/17501911.2025.2479420","DOIUrl":"10.1080/17501911.2025.2479420","url":null,"abstract":"<p><strong>Aims: </strong>This research aims to establish a chromatin regulator (CR) signature to provide new epigenetic insights into the pathogenesis of primary open-angle glaucoma (POAG).</p><p><strong>Materials & methods: </strong>The expression profile of CRs in trabecular meshwork (TM) tissues was analyzed by bioinformatics analysis; The selected hub CRs were further verified by cell experiments.</p><p><strong>Results: </strong>We found the immune microenvironment of the TMwas changed in POAG patients and identified 3 differentially expressed CRs that were relevant to immunity. Then, we successfully constructed and proved a predicted signature based on these 3 CRs, which could effectively predict the risk of POAG. The genes co-expressed with these 3 CRs and miRNAs with are gulatory relationship were identified, and a miRNA-hub CR network was successfully constructed. The results of the Gene Set Enrichment analysis indicated that these 3 hub CRs were all associated with neurodegenerative diseases. Moreover, the human trabecular meshwork cell (HTMC) oxidative stress model was constructed, and KDM5B was significantly down-regulated in this cell model. Finally, we found 10 agents that might be helpful for patients with POAG.</p><p><strong>Conclusions: </strong>Dysregulation of CR expression in TM tissues may be involved in the occurrence and progression of POAG through multiple mechanisms.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"377-387"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EpigenomicsPub Date : 2025-04-01Epub Date: 2025-02-21DOI: 10.1080/17501911.2025.2467024
Fangfang Zhang, Todd Evans
{"title":"Stage-specific DNA methylation dynamics in mammalian heart development.","authors":"Fangfang Zhang, Todd Evans","doi":"10.1080/17501911.2025.2467024","DOIUrl":"10.1080/17501911.2025.2467024","url":null,"abstract":"<p><p>Cardiac development is a precisely regulated process governed by both genetic and epigenetic mechanisms. Among these, DNA methylation is one mode of epigenetic regulation that plays a crucial role in controlling gene expression at various stages of heart development and maturation. Understanding stage-specific DNA methylation dynamics is critical for unraveling the molecular processes underlying heart development from specification of early progenitors, formation of a primitive and growing heart tube from heart fields, heart morphogenesis, organ function, and response to developmental and physiological signals. This review highlights research that has explored profiles of DNA methylation that are highly dynamic during cardiac development and maturation, exploring stage-specific roles and the key molecular players involved. By exploring recent insights into the changing methylation landscape, we aim to highlight the complex interplay between DNA methylation and stage-specific cardiac gene expression, differentiation, and maturation.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"359-371"},"PeriodicalIF":3.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}